Editorial |

Dietary Modification and Risk of Breast Cancer

Aman U. Buzdar, MD
JAMA. 2006;295(6):691-692. doi:10.1001/jama.295.6.691.
Text Size: A A A
Published online


Breast cancer is the second most common cancer in the world and the most common cancer among women in the United States and in other Western countries.1 The incidence rate is about 5 times higher in Western countries than in developing countries.2 Measurable success in multifaceted approaches for prevention and treatment has reduced breast cancer mortality in the United States and in a number of Western countries.3 These approaches include mammography screening, identification of very high-risk families with deleterious mutations within the BRCA1 and BRCA2 genes, and optimal use of adjuvant therapies with endocrine agents, chemotherapeutic agents, and biologically targeted therapy in patients with ERBB2-positive (HER2) disease.47 A woman's risk of developing breast cancer in the next few years and/or her lifetime risk can be estimated using risk assessment tools.8 In women at risk of developing breast cancer, pharmacological interventions with antiestrogens (tamoxifen and raloxifene) can reduce this risk.9 However, these pharmacological interventions are associated with significant adverse effects and have not been adopted on a large scale.10 Aromatase inhibitors also are under evaluation for the at-risk population.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Cancer control in Bangladesh. Jpn J Clin Oncol 2013;43(12):1159-69.
[Epidemiology of breast cancer]. Rev Prat 2013;63(10):1362-6.